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Introduction: Methotrexate is often administered intrathecally or into the cerebral ventricles, particularly in patients
with central nervous system tumors. However, in addition to chemical arachnoiditis, methotrexate can induce severe
myelopathy.
Case presentation: A 59-year-old Japanese man with diffuse B-cell lymphoma who underwent systemic chemotherapy
including methotrexate and 20Gy of radiotherapy received intrathecal methotrexate for recurrence. Flaccid paresis of his
lower limbs and fecal and urinary incontinence appeared 1 month later. All sensations were impaired below the Th10
dermatome level. Although the clinical symptoms were compatible with transverse myelitis, T2-weighted imaging of his
thoracic spinal cord demonstrated signal hyperintensity localized to the posterior and lateral funiculi, which resembled
subacute combined degeneration. His serum vitamin B12, folic acid, and total homocysteine levels were within normal
limits, but total homocysteine levels in his cerebrospinal fluid were elevated, suggesting spinal cord demyelination.
Conclusions: Little is known of the pathogenesis of methotrexate myelopathy. A possible mechanism of methotrexate
myelopathy with demyelination was suggested by the increased homocysteine levels in the cerebrospinal fluid.
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Methotrexate (MTX) suppresses DNA synthesis and prolif-
eration of tumor cells by preventing the conversion of
dihydrofolate to tetrahydrofolate (THF) [1]. MTX shows
minimal transfer through the blood–brain barrier of the
central nervous system (CNS), thus, it is often adminis-
tered intrathecally. MTX can induce confusion, headaches,
or seizures in the acute phase and severe myelopathy in the
subacute phase [1]. Here, we report the case of a patient
who developed transverse myelitis after intrathecal MTX
therapy for malignant lymphoma and postulate a mechan-
ism for MTX myelopathy.
Case presentation
A 59-year-old Japanese man complained of pain in his
lower right leg. Abdominal magnetic resonance imaging
(MRI) revealed a right pelvic tumor compatible with histo-
logical findings of non-Hodgkin diffuse B-cell lymph-
oma. CODOX-M/IVAC (CODOX-M: cyclophosphamide,* Correspondence: kemurata@wakayama-med.ac.jp
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ifosfamide, etoposide, and high-dose cytarabine) was
started, and shrinkage of the tumor was achieved. At 5
months after CODOX-M/IVAC therapy, he complained
of dysesthesia of his bilateral feet. He began taking methyl-
cobalamin, but there was no improvement. Spinal MRI
revealed another mass anterior to the 2nd to 3rd sacral
vertebral bodies. Cerebrospinal fluid (CSF) cytology showed
malignant findings after 20Gy radiation therapy. CODOX-
M/IVAC was administered a second time, and two admin-
istrations of intrathecal MTX (15mg) were started, with
the addition of calcium folinate. Because flaccid paresis
of his lower limbs and fecal and urinary incontinence
appeared 1 month later, he was referred to our department.
His blood pressure was 102/72mmHg and body
temperature was 36.7°C. A neurological examination re-
vealed that he was alert and well oriented. His mental
status was normal, and his cranial nerves appeared in-
tact. He showed flaccid paresis of his lower limbs with
an absence of tendon reflexes and both fecal and urinary
incontinence. Extensor plantar responses were noted
on the left side. Pinprick, light touch, vibration, andrticle distributed under the terms of the Creative Commons Attribution License
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. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Murata et al. Journal of Medical Case Reports  (2015) 9:135 Page 2 of 4proprioception sensations were impaired below the Th10
dermatome level. Cerebellar ataxia was not observed.
Laboratory results revealed normocytic anemia. His
serum vitamin B12 levels were 2788pg/mL and all other
tests showed unremarkable results (copper, 132μg/dL;
total homocysteine, 8.7nmol/mL; and folic acid, 7.6ng/dL).
A CSF examination showed cytoalbuminic dissociation
(mononuclear cells, 1/mm3; protein, 123mg/dL) and a
glucose level of 47mg/dL (blood sugar, 98mg/dL). Myelin
basic protein levels were 3087pg/mL and his CSF homo-
cysteine levels were 1.2nmol/mL. Negative results were
obtained for CSF oligoclonal bands, soluble interleukin-2
receptor, CSF cytology, and polymerase chain reaction
testing for various viruses. Our patient denied all genetic
analysis including homocysteine metabolism.
Findings from brain MRI were unremarkable, but spinal
MRI revealed signal hyperintensity on T2-weighted imaging
in the posterior funiculus of his cervical spinal cord and in
the lateral and posterior funiculi of his thoracic spinal cord
(Fig. 1).
Leucovorin calcium at 60mg/day and high-dose vitamin
B12 replacement therapy were administered for 2 weeks,
but no improvements were observed. He died 3 months
later due to progression of the primary disease.A
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Fig. 1 Conventional T2-weighted magnetic resonance imaging of the cervical
methotrexate. a Sagittal image shows signal hyperintensity (arrows) in the cerv
(arrows) in the thoracic spine from Th4 to Th11. c Coronal image shows s
d Coronal image shows signal hyperintensity in bilateral dorsal columns aDiscussion
In this study, we described a 59-year-old man diagnosed
with non-Hodgkin diffuse B-cell lymphoma. He showed
symptoms of transverse myelitis after intrathecal MTX
therapy. MRI findings in the dorsal and lateral columns
along with the caudal-to-rostral extension of affected re-
gions resembled those of subacute combined degeneration
(SCD). The clinical features of SCD are pyramidal signs
and impaired deep sensation. Our patient showed trans-
verse myelitis, which is very rare in patients with SCD.
Thus, his clinical and MRI findings indicated MTX myel-
opathy (Table 1).
Vacuolar degeneration in the white matter without
inflammatory cell infiltration is the main pathological
finding of MTX myelopathy, according to postmortem
studies. Indeed, demyelination is most prominent in the
posterior funiculus, but has been observed in both the
lateral and anterior funiculi [2]. Furthermore, demyelin-
ation is severe at the surface of the spinal cord in contact
with the CSF, whereas white matter lesions in the center
of the spinal cord appear mild [3]. Such findings suggest
that the demyelination starts from the surface of the
spinal cord and progresses centrally. Even MRI findings
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1 28/F NHL 12mg ×8 + Subacute + C-S (posterior and lateral
funiculi)
Normal/normal Mild Lu et al. [8]
2 60/F NHL 12mg ×9 – Subacute – C-S (posterior funiculus) Normal/N.D. No Lu et al. [8]
3 26/F ALL 12mg ×3 + Acute + C-T (posterior funiculus) Normal/N.D. Mild Counsel and
Khangure [9]
4 45/M ALL 15mg ×7 + Subacute + T-S (posterior and lateral
funiculi)
N.D. No Honda and
Ujihira [10]
5 42/F ALL 12mg ×2 – Subacute – C-T (posterior and lateral
funiculi)
High/normal No Gosavi et al. [11]
6 59/M NHL 14mg ×5 + Subacute + C-T (posterior and lateral
funiculi)
Normal/normal No Our study
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cord, resulting in transverse myelopathy.
Intrathecal MTX administration inhibits the production
of THF and decreases intrathecal 5-methyl-THF produc-
tion [4]. The methyl residue from 5-methyl-THF is re-
quired to convert cobalamin into methylcobalamin, and
methylcobalamin is essential for the synthesis of methio-
nine from homocysteine. Homocysteine levels in CSF are
normally ≤0.5nmol/mL in healthy individuals [5], and can
increase up to 1.0nmol/mL with systemic MTX adminis-
tration [4]. In the present case, the total homocysteine
level in CSF increased to 1.2nmol/mL, whereas that in
serum remained within normal limits. The increased
homocysteine levels in CSF reflect methionine synthesis
disruption in the CNS. S-adenosylmethionine (SAM) is
synthesized from methionine and is indispensable for
the maintenance of the myelin sheath [6]. Intrathecal
MTX administration eventually decreases SAM synthe-
sis, and SAM deficiency in turn induces demyelination
in the spinal cord [6]. An increased level of myelin basic
protein also suggests spinal cord demyelination. Substi-
tution with multiple metabolites may be a promising
strategy for the treatment of MTX-induced neurotoxicity;
however, we had no chance to try these therapies before
the patient died [7].
Conclusions
We have postulated a possible mechanism of MTX myel-
opathy with demyelination from the biochemical perspec-
tive. However, further studies examining a large number
of patients with MTX myelopathy are needed to confirm
our hypothesis.
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